Friday 10th August 2012 |
Text too small? |
Milford Funds, a unit of Milford Asset Management that discloses its financial results, reported a jump in annual fees, driving up profit, as growth in funds under management and improved results lifted performance fees.
Profit rose to $1.05 million in the year ended March 31, from $119,509 a year earlier, according to the Auckland-based company's financial statements. Fees, its principal source of funding, jumped to $5.3 million from $1.76 million.
Expenses climbed to $3.87 million from about $1.6 million, with the biggest increase coming from a management services fee payable to parent Milford Asset.
Milford's funds under management now exceed $1 billion, according to FundSource. In the June quarter, the company had the fourth-fastest inflow of funds in the market and in terms of performance, its Active Growth Fund and Income Fund were the top-performers in those sectors, and its Trans-Tasman Fund was No. 2 in its sector, FundSource said.
In the year ended March 31, Milford exceeded the 10 percent return hurdle required to trigger its best-ever performance fee, managing director Anthony Quirk told BusinessDesk. "We've had very high growth (in funds) and a fantastic investment performance. If clients do well, we do well."
Quirk said Milford is "ahead of budget in terms of revenue growth" for the current year.
Milford Asset, formed in 2003, is a closely held company with 11 shareholder allocations listed on the Companies Office website.
Of the 1.8 million shares on issue, high profile media commentator and Milford director Brian Gaynor owns 450,000, or about 25 percent of the company. Interests associated with director Graeme Thomas and managing director Anthony Quirk each own about 12 percent.
BusinessDesk.co.nz
No comments yet
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report